Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — Technical Presentation (March 2025)
12 slides from Cg Oncology's technical presentation, Mar 12, 2025
Slide 1: Encore Results: BOND-003 Cohort C Phase 3 Study of Cretostimogene Grenadenorepvec
Encore Results: BOND-003 Cohort C- A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for BCG-Unresponsive High- Risk Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ For individual reference only. Mark Tyson, Edward Uchio, Jong-kil Nam, Donald Lamm, Trinity J. Bival
Slide 2: Disclosures
Disclosures • CG Oncology- No Conflicts of Interest Emory University School of Medicine Department of Urology
Slide 3: What is Cretostimogene Grenadenorepvec
What is Cretostimogene Grenadenorepvec • Conditionally replicating adenovirus Cretostimogene in Cancer Cells • Highly immunogenic P P Rb Rb Cell Cycle • Insertion of human E2F-1 promoter P P Progression • Selective for RB-E2F pathway alterations E2F Cretostimogene replicates in and lyses cancer cell
Slide 4: Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS
Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS HR BCG-Unresponsive NMIBC Cretostimogene Grenadenorepvec Primary Endpoint: Single-Arm, Open-Label, IVE Administration CR at Any Time Population Study Design / Regimen Additional Endpoints • Enrollment complete (n=112) I
Slide 5: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics Subjects in Safety Dataset N=112 % Gender • Majority of patients are: Male 83 74.1 • Male (74%) Female 29 25.9 Age (Years) • White (61%) Mean (SD) 72.9 (9.19) • > 65 years (83%) Median (Range) 74.0 (43-90) Age (Categories) • 63.4% of patients in US < 6
Slide 6: Compelling Efficacy & Durability Data: Overall Complete Response
Compelling Efficacy & Durability Data Overall Complete Response CR CR Rate, % CR by K-M Est, % 74.5% 100 Landmark (95% CI) (95% CI) (95% CI, 65.4 % - 82.4 %) 46% (36.9, 56.1)1 12-month 51 out of 110 patients 50% (39.6, 58.9) 75 Overall CR Rate (%) There are 25 confirmed CRs 24-month that have reache
Slide 7: Cretostimogene Demonstrates Sustained Duration of Response
Cretostimogene Demonstrates Sustained Duration of Response Probability (%) Duration of Response in HR BCG-UR NMIBC • Median DoR not yet reached, but exceeds 27 months • Median follow-up in responders not yet reached, but at least 14.5 months • Suggests innate to adaptive switching with immunologic m
Slide 8: Sustained Responses Observed over Months
Sustained Responses Observed over 30 Months • 50.0% of patients reinduced with oncolytic immunotherapy Responders (N=82) converted to CR • 64.3% remain in durable response after conversion to CR • Patients remain in response after treatment completion Time from First Treatment (Months) Emory Univers
Slide 9: CR Rate Consistent Among Patient Subgroups
CR Rate Consistent Among Patient Subgroups Emory University School of Medicine Department of Urology
Slide 10: Favorable & Well-Tolerated Safety Profile
Favorable & Well-Tolerated Safety Profile Cretostimogene (n=112) Preferred Term (MedDRA v.26.1) • 0% Grade ≥ 3 treatment-related AEs Any Grade (%) Grade ≥ 3 or deaths reported Patients with ≥ 1 TRAE 72 (64.3%) 0 (0) • Most AEs were Grade 1-2 Treatment-Related AE reported in > 10% patients Bladder Sp
Slide 11: Key Takeaways
Key Takeaways • Cretostimogene grenadenorepvec provides compelling CR rate (74.5%) • Durable responses • Median DoR not reached but exceeds 27 months • 63.5% (95% CI 51.2%- 73.4%) remain in response at 12 months • Very well-tolerated regimen • No grade 3+ TRAE or discontinuations • 97.3% completed a
Slide 12: Thank You
Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses Mark Tyson Mayo Clinic, AZ, USA Hong Koo Ha Pusan National University Hospital, S. Korea Roger Li Moffitt Cancer Center, FL, USA Kiyohide Fujimoto Nara Medical University Hospital, Japan Jong-Kil N